Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials

The Lancet Diabetes and Endocrinology

Volumn 6, Issue 9, 2018, Pages 691-704

  Perkovic, Vlado ^a,b   de Zeeuw, Dick ^c   Mahaffey, Kenneth W ^d   Fulcher, Greg ^b   Erondu, Ngozi ^e   Shaw, Wayne ^e   Barrett, Terrance D ^e   Weidner Wells, Michele ^e   Deng, Hsiaowei ^e   Matthews, David R ^f   Neal, Bruce ^a,b,g,h  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; CREATININE; HEMOGLOBIN A1C; PLACEBO;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CREATININE BLOOD LEVEL; DIABETIC KETOACIDOSIS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FRACTURE; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; TREATMENT OUTCOME; URINARY ALBUMIN TO CREATININE RATIO; URINARY TRACT FUNCTION; ALBUMINURIA; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG EFFECT; GLOMERULUS FILTRATION RATE; KIDNEY DISEASE; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; URINE;

ADULT; ALBUMINURIA; CANAGLIFLOZIN; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; MALE; PROPORTIONAL HAZARDS MODELS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85048935795     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(18)30141-4     Document Type: Article

References (38)

1. US Renal Data System. 2016 USRDS annual data report: epidemiology of kidney disease in the United States, volume 2. End-stage renal disease in the United States. https://www.usrds.org/2016/download/v2_ESRD_16.pdf, 2016. (Accessed 18 April 2018)
2. Liyanage, T, Ninomiya, T, Jha, V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385 (2015), 1975–1982.
3. Stratton, IM, Adler, AI, Neil, HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000), 405–412.
4. Zoungas, S, Arima, H, Gerstein, HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 5 (2017), 431–437.
5. Perkovic, V, Heerspink, HL, Chalmers, J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 83 (2013), 517–523.
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Working Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3 (2013), 1–150.
7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998), 703–713.
8. Xie, X, Atkins, E, Lv, J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387 (2016), 435–443.
9. Heerspink, HJ, Kröpelin, TF, Hoekman, J, de Zeeuw, D, Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 26 (2015), 2055–2064.
10. Brenner, BM, Cooper, ME, de Zeeuw, D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001), 861–869.
11. Lewis, EJ, Hunsicker, LG, Clarke, WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001), 851–860.
12. Wenzel, RR, Littke, T, Kuranoff, S, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 20 (2009), 655–664.
13. Parving, HH, Brenner, BM, McMurray, JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 (2012), 2204–2213.
14. de Zeeuw, D, Akizawa, T, Audhya, P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369 (2013), 2492–2503.
15. Fried, LF, Emanuele, N, Zhang, JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369 (2013), 1892–1903.
16. Cherney, DZ, Perkins, BA, Soleymanlou, N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
17. Mudaliar, S, Polidori, D, Zambrowicz, B, Henry, RR, Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 38 (2015), 2344–2353.
18. Neal, B, Perkovic, V, Mahaffey, KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
19. Wanner, C, Inzucchi, SE, Lachin, JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
20. Neal, B, Perkovic, V, Mahaffey, KW, et al. Optimizing the analysis strategy for the CANVAS Program: a pre-specified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 19 (2017), 926–935.
21. Neal, B, Perkovic, V, de Zeeuw, D, et al. Rationale, design, and baseline characteristics of the CANagliflozin cardioVascular Assessment Study (CANVAS)—a randomized placebo-controlled trial. Am Heart J 166 (2013), 217–223.
22. Neal, B, Perkovic, V, Matthews, DR, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 19 (2017), 387–393.
23. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. December http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/%20Guidances/UCM071627.pdf2008, 2008. (Accessed 16 March 2018)
24. Peake, M, Whiting, M, Measurement of serum creatinine—current status and future goals. Clin Biochem Rev 27 (2006), 173–184.
25. Levey, AS, Inker, LA, Matsushita, K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 64 (2014), 821–835.
26. Sontrop, JM, Al-Jaishi, AA, Garg, AX, GFR decline as an alternative end point in clinical trials to prevent ESRD: are we increasing treatment uncertainty for the sake of feasibility?. Am J Kidney Dis 64 (2014), 841–844.
27. Thompson, A, Lawrence, J, Stockbridge, N, GFR decline as an end point in trials of CKD: a viewpoint from the FDA. Am J Kidney Dis 64 (2014), 836–837.
28. Levey, AS, Coresh, J, Greene, T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53 (2007), 766–772.
29. Tsiatis, AA, DeGruttola, V, Wulfsohn, S, Modeling the relationship of survival of longitudinal data measured with error. Applications to survival and CD4 counts in patients with AIDS. J Am Stat Assoc 90 (1995), 27–37.
30. Parving, H-H, Lambers-Heerspink, H, de Zeeuw, D, Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 1800–1801.
31. Wanner, C, Inzucchi, SE, Zinman, B, Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 1801–1802.
32. Wong, MG, Perkovic, V, Chalmers, J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39 (2016), 694–700.
33. Heerspink, HJ, Desai, M, Jardine, M, Balis, D, Meininger, G, Perkovic, V, Canagliflozin slows progression of renal function decline independent of glycemic effects. J Am Soc Nephrol 28 (2017), 368–375.
34. Lv, J, Ehteshami, P, Sarnak, MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185 (2013), 949–957.
35. Cornel, JH, Bakris, GL, Stevens, SR, et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care 39 (2016), 2304–2310.
36. Mosenzon, O, Leibowitz, G, Bhatt, DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care 40 (2017), 69–76.
37. Mann, JFE, Ørsted, DD, Brown-Frandsen, K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377 (2017), 839–848.
38. Boehringer Ingelheim. Empagliflozin (Jardiance) to be studied in chronic kidney disease. https://www.boehringer-ingelheim.com/press-release/empagliflozin-be-studied-chronic-kidney-disease (accessed Feb 1, 2018).